147 related articles for article (PubMed ID: 35729702)
21. The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma.
Todeschini L; Cristin L; Martinino A; Mattia A; Agnes S; Giovinazzo F
Curr Oncol; 2023 Jun; 30(6):5574-5592. PubMed ID: 37366904
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
23. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Schnitzbauer AA; Filmann N; Adam R; Bachellier P; Bechstein WO; Becker T; Bhoori S; Bilbao I; Brockmann J; Burra P; Chazoullières O; Cillo U; Colledan M; Duvoux C; Ganten TM; Gugenheim J; Heise M; van Hoek B; Jamieson N; de Jong KP; Klein CG; Klempnauer J; Kneteman N; Lerut J; Mäkisalo H; Mazzaferro V; Mirza DF; Nadalin S; Neuhaus P; Pageaux GP; Pinna AD; Pirenne J; Pratschke J; Powel J; Rentsch M; Rizell M; Rossi G; Rostaing L; Roy A; Scholz T; Settmacher U; Soliman T; Strasser S; Söderdahl G; Troisi RI; Turrión VS; Schlitt HJ; Geissler EK
Ann Surg; 2020 Nov; 272(5):855-862. PubMed ID: 32889867
[TBL] [Abstract][Full Text] [Related]
24. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
25. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.
Ferrín G; Guerrero M; Amado V; Rodríguez-Perálvarez M; De la Mata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070029
[TBL] [Abstract][Full Text] [Related]
26. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.
Thomas HE; Mercer CA; Carnevalli LS; Park J; Andersen JB; Conner EA; Tanaka K; Matsutani T; Iwanami A; Aronow BJ; Manway L; Maira SM; Thorgeirsson SS; Mischel PS; Thomas G; Kozma SC
Sci Transl Med; 2012 Jun; 4(139):139ra84. PubMed ID: 22539746
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
[TBL] [Abstract][Full Text] [Related]
28. Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.
Huynh H; Ng WH; Soo KC
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203186
[TBL] [Abstract][Full Text] [Related]
29. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis.
Ma YS; Lv ZW; Yu F; Chang ZY; Cong XL; Zhong XM; Lu GX; Zhu J; Fu D
J Exp Clin Cancer Res; 2018 Oct; 37(1):252. PubMed ID: 30326936
[TBL] [Abstract][Full Text] [Related]
32. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis.
Wu Y; Xu X; Liu M; Qin X; Wu Q; Ding H; Zhao Q
Biochem Pharmacol; 2022 Jul; 201():115093. PubMed ID: 35580648
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma.
Gao C; Wang S; Shao W; Zhang Y; Lu L; Jia H; Zhu K; Chen J; Dong Q; Lu M; Zhu W; Qin L
Front Med; 2022 Jun; 16(3):467-482. PubMed ID: 34669157
[TBL] [Abstract][Full Text] [Related]
34. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
Lu X; Paliogiannis P; Calvisi DF; Chen X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):49-61. PubMed ID: 32394479
[TBL] [Abstract][Full Text] [Related]
35. The activation of mTOR signalling modulates DNA methylation by enhancing DNMT1 translation in hepatocellular carcinoma.
Chen M; Fang Y; Liang M; Zhang N; Zhang X; Xu L; Ren X; Zhang Q; Zhou Y; Peng S; Yu J; Zeng J; Li X
J Transl Med; 2023 Apr; 21(1):276. PubMed ID: 37088830
[TBL] [Abstract][Full Text] [Related]
36. MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7.
Zhao Y; Zhu C; Chang Q; Peng P; Yang J; Liu C; Liu Y; Chen X; Liu Y; Cheng R; Wu Y; Wu X; Hu L; Yin J
PLoS One; 2020; 15(11):e0242179. PubMed ID: 33201900
[TBL] [Abstract][Full Text] [Related]
37. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
[TBL] [Abstract][Full Text] [Related]
38. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
[TBL] [Abstract][Full Text] [Related]
39. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.
Hudson CC; Liu M; Chiang GG; Otterness DM; Loomis DC; Kaper F; Giaccia AJ; Abraham RT
Mol Cell Biol; 2002 Oct; 22(20):7004-14. PubMed ID: 12242281
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]